Rimegepant

Real-world studies of CGRP monoclonal antibodies and gepants for migraine 5:33
Real-world studies of CGRP monoclonal antibodies and gepants for migraine
Chia-Chun Chiang • 3 Apr 2022
Advantages of oral anti-CGRP drugs in migraine prevention 14:28
Advantages of oral anti-CGRP drugs in migraine prevention
Sait Ashina • 17 Mar 2022
The evolutionary importance of CGRP 2:21
The evolutionary importance of CGRP
Lawrence Robbins • 23 Sep 2021
Flexible use of rimegepant for migraine 0:57
Flexible use of rimegepant for migraine
Christopher Jensen • 10 Sep 2021
Rimegepant for migraine: rapid onset of preventive treatment effects 1:12
Rimegepant for migraine: rapid onset of preventive treatment effects
Christopher Jensen • 14 Sep 2021
Onset of migraine preventive effects with rimegepant in a Phase II/III trial 2:02
Onset of migraine preventive effects with rimegepant in a Phase II/III trial
Christopher Jensen • 14 Sep 2021
Beyond CGRP: psychedelics for the treatment of migraine 4:16
Beyond CGRP: psychedelics for the treatment of migraine
Jessica Ailani • 21 Jun 2021
Rimegepant to treat acute migraine in patients with cardiovascular risk factors 2:36
Rimegepant to treat acute migraine in patients with cardiovascular risk factors
Susan Hutchinson • 21 Apr 2021
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant 3:02
Upcoming treatments for migraine: zavegepant, rimegepant and atogepant
Jessica Ailani • 18 Apr 2021
Challenges in migraine management 2:09
Challenges in migraine management
Uwe Reuter • 22 May 2020
The evolving landscape of migraine treatment and prevention 3:42
The evolving landscape of migraine treatment and prevention
Uwe Reuter • 22 May 2020
The content of VJNeurology is intended for healthcare professionals